Outcomes and Predictors of Perinatal Mortality in Fetuses With Ebstein Anomaly or Tricuspid Valve Dysplasia in the Current Era: A Multicenter Study
Ebstein anomaly and tricuspid valve dysplasia are rare congenital tricuspid valve malformations associated with high perinatal mortality. Previous literature has consisted of single-center series, often spanning several decades. We report a series of 243 fetuses with Ebstein anomaly or tricuspid valve dysplasia from 23 centers across North America in the recent era. Unfortunately, perinatal mortality remained high at 45%, with one-third of patients not surviving to neonatal hospital discharge. Independent risk factors for mortality included gestational age at diagnosis of <32 weeks, larger tricuspid valve annulus z-score, the presence of pulmonary regurgitation, and a pericardial effusion. The presence of pulmonary regurgitation, in particular, signifies circular shunt physiology, which often culminated in mortality. An understanding of this unique physiology in utero may help clinicians better counsel expectant parents, develop and pursue novel treatment and perinatal management strategies, and ultimately improve mortality for fetuses with this rare and complex disease. See p 481.
Hck/Fgr Kinase Deficiency Reduces Plaque Growth and Stability by Blunting Monocyte Recruitment and Intraplaque Motility
Atherosclerosis, a major underlying cause for cardiovascular disorders is a chronic lipid-driven inflammatory disease that is impacted by many risk factors: hypertension, dyslipidemia, type 2 diabetes mellitus, etc. Current drug therapy appears to reduce the risk of future cardiovascular events in 30% of patients, urging for new complementary medication to also reduce risk in poorly responding patients. It is in this context that inflammation has been embraced as a potential target for intervention. In particular, the accumulation and activity in atherosclerotic plaque of potentially deleterious leukocyte subsets have so far been investigated for their effectiveness to quench plaque inflammation and improve its stability, both in preclinical and, albeit with little success, in clinical studies. In this study, we have interrogated the therapeutic potential of inhibition of the mobility of plaque macrophages, the abundant presence of which is viewed as a hallmark of the vulnerable plaque. We are the first to show that hyperlipidemic mice with blunted expression of 2 drugable regulators of phagocyte mobility (the kinases Hck and Fgr) have smaller plaques, which paradoxically display clear features of increased vulnerability, such as thinned fibrous caps. We were able to demonstrate that this may be caused by trapping newly invaded phagocytes in the fibrous cap region, creating a lytic milieu that will affect focal erosion. Our findings thus raise a note of caution regarding the therapeutic value of Hck and Fgr as key targets for intervention in plaque inflammation. See p 490.
Association of Interstage Home Monitoring With Mortality, Readmissions, and Weight Gain: A Multicenter Study from the National Pediatric Cardiology Quality Improvement Collaborative
Children with single-ventricle heart disease face a high risk of mortality during the interstage period, the period after discharge from stage I palliation and before stage II palliation. Home monitoring of these infants with oxygen saturation monitoring (via pulse oximetry) or monitoring of weight gain (via infant scales) has been shown in some centers to decrease this mortality, but those prior studies were limited to single centers or used historical control subjects. In this study using prospective data collected on 509 patients from 2008 to 2012 at 50 centers in the National Pediatric Cardiology Quality Improvement collaborative, there was no association of home monitoring of oxygen saturation or weight with mortality, mortality/transplantation, or unscheduled readmissions. Home weight monitoring, however, was associated with improved interstage weight gain, and greater weight at time of stage II palliation has previously been shown to be associated with improved outcomes after that operation. Furthermore, there may be benefits to home monitoring of infants with a single ventricle beyond those measured in this study, particularly the psychological effects of home monitoring on parents. Importantly, overall mortality was lower in this cohort than in previous multicenter cohorts in which interstage mortality was studied, a finding that suggests that improved overall care coordination, of which home monitoring is a component at most centers, may be a key driver in improved interstage outcomes. Although overall interstage mortality may be decreasing over time for this vulnerable population, further efforts are needed if the goal of 0% interstage mortality is to be realized. See p 502.
Cerebral Microbleeds Are Associated With an Increased Risk of Stroke: The Rotterdam Study
During the past decade, cerebral microbleeds have emerged as a potential early imaging marker of stroke. Most studies thus far have focused on the risk of stroke recurrence in patients with microbleeds who were admitted for stroke. Very little is known about the clinical relevance of microbleeds in the stroke-free general population, whereas microbleeds are highly prevalent in community-dwelling individuals. Results from our population-based study provide multiple new insights into the association of microbleeds and stroke. First, we found that microbleeds increase the risk of first-ever stroke, both ischemic and hemorrhagic, in the general population. Second, we found that the location of microbleeds in the brain may relate to the risk of specific stroke subtypes. Third, we observed an intriguing spatial colocalization between the site of microbleeds and the region of hemorrhagic stroke. The clinical implications of our findings are 2-fold. First, our data add importantly to evidence that microbleeds are risk indicators of clinical stroke, and take this beyond the patient-based level to the population Volume 132 ◼ Number 6 ◼ August 11, 2015 level. Not only does this add crucial insight into stroke etiology and pathophysiology, it has implications for future studies on the use of imaging markers for stroke prediction. Second, our current data, combined with increasing evidence of an association between microbleeds and antithrombotic treatment, strongly support the inclusion of microbleed-sensitive imaging in clinical trials for primary and secondary stroke prevention to assess whether outcomes and treatment effects interact with microbleed presence. See p 509.
Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study
Patients with atrial fibrillation who survive an intracranial hemorrhage (ICH) are at an increased risk of subsequent ischemic stroke. Thus, a major unanswered question concerns the efficacy and safety of restarting oral anticoagulant (OAC) treatment, relative to not restarting OAC, following a presentation with ICH. This observational study includes patients sustaining an incident ICH event who are discharged from the hospital, and reports on outcomes of ischemic events, all-cause mortality, and recurrent bleeding. The data were obtained from Danish nationwide registries and comprises a total of 1752 patients. We found a significantly increased event rate (per 100 person-years) of a combined end point of ischemic stroke/systemic embolism and all-cause mortality in patients who did not resume OAC treatment in comparison with patients who did resume OAC treatment: 27.3 versus 13.6 and 25.7 for patients who received antiplatelet therapy. The adjusted hazard ratios favored OAC treatment, 0.55 (95% confidence interval, 0.39-0.78), whereas antiplatelet therapy did not entail similar associations, 0.87 (95% confidence interval, 0.67-1.14). We calculated the net clinical benefit as a weighted sum of rate differences for the combined end point of ischemic stroke/systemic embolism and all-cause mortality and recurrent ICH. The net clinical benefit for OAC versus no antithrombotic treatment was 14.6 (95% confidence interval, 6.4-22.8), whereas the net clinical benefit was nonsignificant for antiplatelet therapy versus no antithrombotic treatment, 6.5 (95% confidence interval, -2.1 to 15.2). Despite the inherited limitations of observational data (selection bias and confounding by indication), these data support OAC reintroduction post-ICH. Based on these results, future randomized, controlled trials investigating the resumption of OAC treatment post-ICH are encouraged. See p 517.
